The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

In today’s episode, we explore how the lived experience of someone with rheumatoid arthritis can systematically be documented via the use of patient-reported outcome measures.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

The podcast will explore the personal experiences of people living with rheumatic diseases and the latest research evidence that informs their diagnosis and treatment.

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

Research into global prevalence rates of autoimmune conditions such as multiple sclerosis and psoriasis highlights important information for future research and medical resource allocation.

A beta diversity analyses revealed a distinct clustering pattern between healthy controls and patients with HBV-related liver disease and the composition of bacteria from the phylum level to the genus level varies across the stages of liver disease.

Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.

Experts discuss the use of biologics in the treatment of rare dermatologic disorders.

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

These findings suggest that disparities in reporting data may be present in nursing homes, with implications for surveillance of nursing homes, priority setting for facilities, as well as payment and research.

The results show a moderate certainty on the lack of effect across outcomes and 2 values and preferences studies found participants enjoyed specific counseling behavioral interventions.

Ahead of the May 27, 2023 PDUFA date, the HCPLive Cardiology editorial team spoke to a group of cardiologists to capture their perspective of the potential role of sotagliflozin.

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.

The findings could provide insight into incorporating both OCTA and artificial intelligence for early detection of DMI and better enhancing the management of diabetic retinopathy.

Janssen aims to address health inequities and promote culturally competent care.

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

An analysis of the UK Biobank found menstrual cycles less than 21 days or longer than 35 days were associated with a 19% higher risk of CVD compared with a regular menstrual cycle length.